PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.
The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.
Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.
PMV Pharmaceuticals (Nasdaq: PMVP), un'azienda di oncologia di precisione focalizzata sulle terapie mirate al p53, ha annunciato la sua partecipazione a due importanti conferenze per investitori in arrivo. David H. Mack, Ph.D., Presidente e CEO, e Deepika Jalota, Pharm. D., Direttore Sviluppo, rappresenteranno l'azienda.
Le conferenze includono la 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute il 12 febbraio 2025, alle 12:40 PM EST, e la 45ª Conferenza Annuale TD Cowen sulla Salute il 4 marzo 2025, alle 3:10 PM EST. La Direzione condurrà anche incontri individuali con gli investitori durante questi eventi.
Webcast audio dal vivo saranno disponibili online, con repliche archiviabili accessibili per 90 giorni dopo ogni presentazione attraverso la piattaforma Eventi & Presentazioni dell'azienda.
PMV Pharmaceuticals (Nasdaq: PMVP), una empresa de oncología de precisión centrada en terapias dirigidas al p53, ha anunciado su participación en dos importantes conferencias para inversores que se aproximan. David H. Mack, Ph.D., Presidente y CEO, y Deepika Jalota, Pharm. D., Directora de Desarrollo, representarán a la empresa.
Las conferencias incluyen la 35ª Conferencia Anual Oppenheimer de Ciencias de la Salud el 12 de febrero de 2025, a las 12:40 PM EST, y la 45ª Conferencia Anual TD Cowen de Atención Médica el 4 de marzo de 2025, a las 3:10 PM EST. La dirección también llevará a cabo reuniones individuales con inversores durante estos eventos.
Se ofrecerán webcasts de audio en vivo en línea, con repeticiones archivadas accesibles durante 90 días después de cada presentación a través de la plataforma de Eventos & Presentaciones de la compañía.
PMV Pharmaceuticals (Nasdaq: PMVP)는 p53 표적 치료에 중점을 둔 정밀 종양학 회사로, 다가오는 두 개의 주요 투자자 회의에 참가할 것이라고 발표했습니다. David H. Mack, Ph.D. 사장 겸 CEO와 Deepika Jalota, Pharm. D. 개발 책임자가 회사를 대표합니다.
회의는 2025년 2월 12일 동부 표준시 기준 오후 12시 40분에 열리는 오펜하이머 제35회 연례 의료 생명 과학 회의와 2025년 3월 4일 동부 표준시 기준 오후 3시 10분에 열리는 TD 코웬 제45회 연례 건강 관리 회의를 포함합니다. 경영진은 이러한 이벤트 동안 투자자와의 일대일 회의도 진행합니다.
온라인에서 라이브 오디오 웹캐스트가 제공되며, 각 프레젠테이션 후에는 회사의 이벤트 & 프레젠테이션 플랫폼을 통해 90일 동안 아카이브 재생이 가능합니다.
PMV Pharmaceuticals (Nasdaq: PMVP), une entreprise de cancérologie de précision axée sur des thérapies ciblant le p53, a annoncé sa participation à deux grandes conférences d'investisseurs à venir. David H. Mack, Ph.D., Président et CEO, et Deepika Jalota, Pharm. D., Directrice du Développement, représenteront l'entreprise.
Les conférences incluent la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé le 12 février 2025 à 12h40 EST, et la 45e Conférence Annuelle TD Cowen sur les Soins de Santé le 4 mars 2025 à 15h10 EST. La direction organisera également des réunions individuelles avec les investisseurs lors de ces événements.
Des webcasts audio en direct seront disponibles en ligne, avec des rediffusions archivées accessibles pendant 90 jours après chaque présentation via la plateforme Événements & Présentations de l'entreprise.
PMV Pharmaceuticals (Nasdaq: PMVP), ein Unternehmen für präzise Onkologie mit dem Fokus auf p53-zielgerichtete Therapien, hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen bekannt gegeben. David H. Mack, Ph.D., Präsident und CEO, sowie Deepika Jalota, Pharm. D., Chief Development Officer, werden das Unternehmen vertreten.
Die Konferenzen umfassen die 35. jährliche Oppenheimer-Konferenz für Gesundheits- und Lebenswissenschaften am 12. Februar 2025 um 12:40 Uhr EST und die 45. jährliche TD Cowen Gesundheitskonferenz am 4. März 2025 um 15:10 Uhr EST. Das Management wird während dieser Veranstaltungen auch persönliche Investorenmeetings durchführen.
Live-Audio-Webcasts werden online verfügbar sein, mit archivierten Wiedergaben, die 90 Tage nach jeder Präsentation über die Event- & Präsentationsplattform des Unternehmens zugänglich sind.
- None.
- None.
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025
Time: 12:40 PM EST
TD Cowen 45th Annual Health Care Conference
Date: Tuesday, March 4, 2025
Time: 3:10 PM EST
A live audio webcast of the events will be available online at Events & Presentations. An archived replay of the events will be available for 90 days following the webcast at Events & Presentations.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
FAQ
When is PMV Pharmaceuticals (PMVP) presenting at the Oppenheimer Healthcare Conference in 2025?
What time is PMVP's presentation at the TD Cowen Health Care Conference in March 2025?
How long will the webcasts of PMVP's investor conference presentations be available?
Which executives from PMV Pharmaceuticals will participate in the 2025 investor conferences?
Will PMVP management be available for individual investor meetings at the conferences?
